Finance
Lilly's Obesity Pill Records Modest Second Week as Battle With Novo Intensifies
Published by Global Banking & Finance Review®
Posted on April 24, 2026
2 min readLast updated: April 24, 2026
Add as preferred source on GoogleQuick Summary
Eli Lilly’s newly approved oral weight‑loss pill, Foundayo, saw a modest pickup in week two with 3,707 U.S. prescriptions versus 1,390 in its debut week. In contrast, Novo Nordisk’s oral Wegovy achieved about 18,410 scripts in its second week, intensifying the competitive pressure in the oral obesit
Lilly's Foundayo Obesity Pill Trails Novo's Wegovy in Early US Rollout
Foundayo's Launch Performance and Market Comparison
By Sriparna Roy
April 24 (Reuters) - Eli Lilly's newly launched weight-loss pill had a modest second week, analysts said on Friday, as competition with Danish rival Novo Nordisk heats up in the oral obesity drug market.
Prescription Data: Foundayo vs. Wegovy
The pill, launched earlier this month as Foundayo, was prescribed 3,707 times in the U.S. in the week ended April 17, IQVIA data shared by Wall Street analysts showed, up from 1,390 in its debut week.
Novo's Wegovy pill, launched in January, had clocked 18,410 prescriptions in its second week and 3,071 in the first four days after launch.
Analyst Expectations and Reactions
Analysts would have liked to see Foundayo's second-week prescriptions closer to around 8,000 "to show that its relative spread to the oral Wegovy launch was at least being maintained," said Deutsche Bank analyst James Shin.
RBC Capital Markets analyst Trung Huynh said while comparisons close to launch "should be considered immaterial, Foundayo's uptake this week is likely to be received negatively."
Market Impact
Lilly shares were trading nearly 4% lower, while U.S.-listed Novo shares were about 6% higher.
Foundayo prescriptions, totaling just 20% of what oral Wegovy achieved during its first full week, were "modest," noted Truist analyst Srikripa Devarakonda.
Rollout Dynamics and Investor Sentiment
Slower Ramp and Market Share Concerns
SLOWER RAMP
Investors are closely watching the rollout as a key test of whether Lilly can gain market share from Novo, which has had a first-mover advantage in the oral weight-loss drug market.
The prescription numbers represent a somewhat slower ramp compared to oral Wegovy, said J.P. Morgan analyst Chris Schott, adding that this was not surprising given Wegovy's advantages in time-to-market and brand recognition.
Distribution and Availability
Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on April 6. Broad availability through U.S. retail pharmacies and telehealth providers began on April 9.
Company Guidance on Early Data
Lilly previously cautioned that early weekly figures would not be fully comprehensive, may not capture the full breadth of pharmacy partners and would be "best interpreted over time rather than as a complete count."
(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid and Jonathan Ananda)
Key Takeaways
- •Foundayo doubled week‑over‑week to 3,707 prescriptions by April 17, still far below Wegovy’s 18,410 in its second week (reddit.com).
- •Analysts expected Foundayo to reach closer to 8,000 scripts second week to maintain relative parity with Wegovy; its slower ramp drew skepticism (reddit.com).
- •Convenience may be Foundayo’s main advantage—it lacks Wegovy’s fasting restrictions—though analysts note its impact may be limited in driving broader uptake (biz.chosun.com).
References
Frequently Asked Questions about Lilly's obesity pill records modest second week as battle with Novo intensifies
1How many Foundayo prescriptions were made in its second week?
Foundayo was prescribed 3,707 times in the US in its second week, up from 1,390 in the debut week.
2How does Foundayo's launch compare to Novo's Wegovy pill?
In its second week, Foundayo prescriptions were around 20% of what oral Wegovy achieved, signaling a slower ramp for Lilly.
3What concerns did analysts raise about Foundayo's initial uptake?
Analysts noted Foundayo's uptake was modest and below expectations, with some anticipating around 8,000 second-week prescriptions.
4How did the competition affect Lilly and Novo's share prices?
Lilly shares dropped nearly 4%, while US-listed Novo shares rose about 6% following the prescription data.
5When did Foundayo become broadly available in the US?
Broad availability of Foundayo through US pharmacies and telehealth providers began on April 9.
